Immunophotonics, Inc. is thrilled to announce the addition of Dr. Edwina Baskin-Bey in the role of Chief Medical Office (CMO) and Dr. David Anderson in the role of Chief Scientific Officer (CSO).  Dr. Baskin-Bey’s vast experience in leading global clinical development and regulatory strategy across multiple therapeutic areas will strengthen the clinical development program as the company expands into Phase 2 trials and beyond.  Dr. Anderson’s proven experience in innovation, which includes facilitating asset development from discovery through approval, will allow Immunophotonics to bolster its research and development initiatives.  Read More